$ISWH “Now that Q3 is in the books, we wanted to
Post# of 8462
Management notes that the remainder of the 2019 fiscal year should be marked by accelerating growth in spirits sales, sales of the Company’s P19 CBD products, and client and sales growth for the Company’s Home Healthcare business. The Company also anticipates the start of P19 CBD product sales in physical stores during this quarter, with details on a new strategic partnership set to be announced over the near-term. Sees Record Q3: 79% Sequential Rev Growth, EBITDA Profitable, Accelerating Growth in Q4
https://www.globenewswire.com/news-release/20...in-Q4.html